North America Infertility Diagnostics Devices Market Report and Forecast 2024-2032

The global infertility diagnostics devices market size is expected to grow at a CAGR of 8.80% during the forecast period of 2024-2032, with North America holding a significant market share. The market is driven by the rising prevalence of infertility along with advancements in diagnostic technologies.

Key Takeaways

• In November 2023, Femasys Inc., secured an upfront investment of USD 6.85 million from PharmaCyte Biotech. The financing will support the commercialization of Femasys infertility-related products, including FemVue, which can help to check tubal infertility or blocked tubes in women. The increased access to such innovative diagnostic devices is likely to augment North America infertility diagnostics devices market share in the forecast years.
• Infertility is a common problem in the United States, with around 11% of women and 9% of men affected by this condition in their reproductive age. Rising infertility burden is likely to elevate market value in the forecast period.
• Intensive research efforts associated with infertility and its treatments are resulting in the development of advanced testing methods. This is are anticipated to boost market growth. In June 2023, researchers at the University of Alberta discovered two unique protein biomarkers that have the potential to provide a non-invasive diagnostic test for men.

North America Infertility Diagnostics Devices Market Analysis

Infertility can be defined as a condition that impairs the body’s ability to reproduce. It can be caused due to issues with the reproductive system of either the male or female partner. In women, the most common cause of infertility includes irregular ovulation, obstructed fallopian tubes, and endometriosis whereas in men, sperm disorders are the common cause of infertility issues. Factors such as lifestyle changes, delayed childbearing, and rising incidence of conditions affecting fertility are contributing to the growing cases of infertility in the region. Heightened patient awareness surrounding infertility along with the reduced stigma attached to seeking treatments for the condition are expected to significantly drive the North America infertility diagnostics devices market demand in coming years.

Rising healthcare expenditure and insurance coverage for infertility treatments in North America are positively influencing the market landscape. Moreover, the increased prevalence of infertility issues in the region directly impacts the demand for infertility diagnostic services and devices. Recent data suggests that infertility is a common problem in the United States, with around 11% of women and 9% of men of child-bearing age affected by this condition. This sharp increase in infertility burden is likely to elevate market value in the forecast period.

The rising investment in the infertility diagnostics sector to address the growing demand for advanced diagnostic solutions is expected to fuel North America infertility diagnostics devices market growth. In November 2023, Femasys Inc., a United States-based biomedical company, secured an upfront investment of USD 6.85 million from PharmaCyte Biotech (a biotechnology company headquartered in the United States). The financing will support the commercialization of Femasys infertility-related products, FemaSeed and FemVue, as well as the development of a broad portfolio of other products. FemVue, the first FDA-cleared diagnostic device for fallopian tube assessment, can help to check for tubal infertility or blocked tubes in women. The increased access to such innovative diagnostic devices is likely to augment market size in the region.

Intensive research efforts associated with infertility and its treatments are resulting in the development of advanced testing methods, which are anticipated to significantly boost North America infertility diagnostics devices market value. In June 2023, a team of researchers at the University of Alberta (a public research university in Canada) discovered two proteins that are only found in viable sperms. These unique protein biomarkers have the potential to provide men with a non-invasive diagnostic test that can offer insights into whether in vitro fertilization can work in certain patients. The development of such innovative diagnostic tests with the ability to predict the success rate of surgery in infertile men is expected to accelerate market growth in coming years.

North America Infertility Diagnostics Devices Market Segmentation

The report offers a detailed analysis of the market based on the following segments:

Market Breakup by Product

• Equipment
• Media & Consumables
• Accessories

Market Breakup by Procedure

• In Vitro Fertilization
• Intracytoplasmic Sperm Injection
• Artificial Insemination
• Fertility Surgeries
• Others

Market Breakup by Patient Type

• Female
• Male

Market Breakup by Type

• Sperm Separation Devices
• Ovum Aspiration Pump
• Sperm Analyzer Systems
• Micromanipulator Systems
• Incubators
• Cryosystems
• Imaging Systems
• Microscope
• Others

Market Breakup by End User

• Hospitals & Surgical Clinics
• Cryobanks
• Research Institutes
• Others

Market Breakup by Countries

• United States of America
• Canada

North America Infertility Diagnostics Devices Market: Competitor Landscape

The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Cook Group
• Vitrolife
• Thermo Fisher Scientific
• Hamilton Thorne LTD
• Esco Micro Pte Ltd
• Genea Limited
• IVFtech APS
• FUJIFILM Irvine Scientific
• The Baker Company Inc.

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

FAQs

What is the North America infertility diagnostics devices market forecast outlook for 2024-2032?
The North America infertility diagnostics devices market is expected to be driven by the rising demand for the global infertility diagnostics devices market, which is anticipated to grow at a CAGR of 8.80% during the forecast period of 2024-2032, driven by the rising prevalence of infertility.

What are the major factors aiding the North America infertility diagnostics devices market demand?
Technological advancements in infertility diagnostics and the rising healthcare expenditure are fuelling the demand for the market.

What are the major North America infertility diagnostics devices market trends?
One of the significant trends in the market is rising investment in the infertility diagnostics sector. In November 2023, Femasys Inc. secured an upfront investment of USD 6.85 million from PharmaCyte Biotech. The financing will support the commercialization of Femasys infertility-related products, including FemVue, which can help to check tubal infertility or blocked tubes in women.

What is the market segmentation based on the product?
Based on the product, the market is segmented into equipment, media, consumables, and accessories.

What are the various procedures available in the market?
Procedures available in the market include in vitro fertilization, intracytoplasmic sperm injection, artificial insemination, and fertility surgeries, among others.

What is the market breakup by patient type?
By patient type, the market is divided into female and male.

What is the market segmentation based on the type?
The market breakup by type includes sperm separation devices, ovum aspiration pumps, sperm analyzer systems, micromanipulator systems, incubators, cryosystems, imaging systems, and microscopes, among others.

What are the major end users of infertility diagnostics devices?
End users include hospitals, surgical clinics, cryobanks, and research institutes, among others.

What is the market segmentation by countries?
The market segmentation by countries includes the United States of America and Canada.

Who are the key players involved in the North America infertility diagnostics devices market?
The key players in the market are Cook Group, Vitrolife, Thermo Fisher Scientific, Hamilton Thorne LTD, Esco Micro Pte Ltd, Genea Limited, IVFtech APS, FUJIFILM Irvine Scientific, and The Baker Company Inc.


This product will be delivered within 5-7 business days.